Speakers

Dr Martina Benešová-Schäfer
German Cancer Research Center
Germany

Dr Martina Benešová-Schäfer
Martina Benešová-Schäfer leads the Junior Research Group Translational Radiotheranostics at the German Cancer Research Center (DKFZ) in Heidelberg, Germany. She studied Nuclear Chemistry and
Clinical Toxicology at Charles University in the Czech Republic and earned her PhD in
Radiopharmaceutical Chemistry from DKFZ. Her postdoctoral training was conducted at the Paul Scherrer Institute (PSI) in Villigen and at ETH Zürich in Switzerland.
Her interdisciplinary research focuses on the physicochemical and biological properties of alpha particle-emitting radionuclides. She specializes in the development of targeted radioligands for diagnostic, prognostic, therapeutic, and theranostic applications. Martina Benešová-Schäfer has made contributions to the development of PSMA-targeting radioligands, including PSMA-617, PSMA-1007, and PSMA-ALB- 56. Driven by a strong commitment to personalized medicine, her work aims to expand treatment options and improve outcomes for patients with limited therapeutic alternatives.
Her interdisciplinary research focuses on the physicochemical and biological properties of alpha particle-emitting radionuclides. She specializes in the development of targeted radioligands for diagnostic, prognostic, therapeutic, and theranostic applications. Martina Benešová-Schäfer has made contributions to the development of PSMA-targeting radioligands, including PSMA-617, PSMA-1007, and PSMA-ALB- 56. Driven by a strong commitment to personalized medicine, her work aims to expand treatment options and improve outcomes for patients with limited therapeutic alternatives.

Dr Brian Gonzalez
Moffitt Cancer Center
USA

Dr Brian Gonzalez
Brian Gonzalez, PhD is Associate Center Director for Research Career Development and Associate Member in the departments of Health Outcomes & Behavior and Genitourinary Oncology at Moffitt Cancer Center.
He is an expert in examining patient-reported outcomes (PROs) among patients with prostate cancer. He also led development of the first PRO measure designed for use with patients receiving radionuclide therapy for prostate cancer. His research focuses on improving quality of life in cancer patients and survivors. He seeks to identify novel risk factors for worsening quality of life and develop interventions to improve quality of life in cancer patients and survivors.
He is an expert in examining patient-reported outcomes (PROs) among patients with prostate cancer. He also led development of the first PRO measure designed for use with patients receiving radionuclide therapy for prostate cancer. His research focuses on improving quality of life in cancer patients and survivors. He seeks to identify novel risk factors for worsening quality of life and develop interventions to improve quality of life in cancer patients and survivors.

Prof Andrei Iagaru
Stanford
USA

Prof Andrei Iagaru
Dr. Iagaru is a Professor of Radiology - Nuclear Medicine and the Chief of the Division of Nuclear Medicine and Molecular Imaging at Stanford University Medical Center. He completed medical school at Carol Davila University of Medicine, Bucharest, Romania, and an internship at Drexel University College of Medicine, Graduate Hospital, in the Department of Medicine in Philadelphia. He began his residency at the University of Southern California (USC) Keck School of Medicine, Los Angeles, in the Division of Nuclear Medicine. Dr. Iagaru finished his residency and completed a PET/CT fellowship at Stanford University's School of Medicine in the Division of Nuclear Medicine. His research interests include PET/MRI and PET/CT for early cancer detection; clinical translation of novel PET radiopharmaceuticals; peptide-based diagnostic imaging and therapy; targeted radionuclide therapy.
Since joining the faculty at Stanford in 2007, Dr. Iagaru has received several awards including the Society of Nuclear Medicine (SNM) 2009 Image of the Year Award; AuntMinnie 2016 Best Radiology Image, American College of Nuclear Medicine (ACNM) Mid-Winter Conference 2010 Best Essay Award; 2009, 2014 and 2015 Western Regional SNM Scientist Award; 2011 SNM Nuclear Oncology Council Young Investigator Award; the 2020 Sanjiv Sam Gambhir Distinguished Scientist Award, Western Regional SNM; the 2022 Sanjiv Sam Gambhir Trailblazer Award, SNMMI; the 2022 Distinguished Investigator Award, The Academy for Radiology & Biomedical Imaging Research and the 2023 Presidential Award, SNMMI. Dr. Iagaru published more than 240 papers in peer-reviewed journals, as well as 9 book chapters and 1 book.
Since joining the faculty at Stanford in 2007, Dr. Iagaru has received several awards including the Society of Nuclear Medicine (SNM) 2009 Image of the Year Award; AuntMinnie 2016 Best Radiology Image, American College of Nuclear Medicine (ACNM) Mid-Winter Conference 2010 Best Essay Award; 2009, 2014 and 2015 Western Regional SNM Scientist Award; 2011 SNM Nuclear Oncology Council Young Investigator Award; the 2020 Sanjiv Sam Gambhir Distinguished Scientist Award, Western Regional SNM; the 2022 Sanjiv Sam Gambhir Trailblazer Award, SNMMI; the 2022 Distinguished Investigator Award, The Academy for Radiology & Biomedical Imaging Research and the 2023 Presidential Award, SNMMI. Dr. Iagaru published more than 240 papers in peer-reviewed journals, as well as 9 book chapters and 1 book.

Prof Tobias Maurer
Martini-Klinik University Medical Centre Hamburg-Eppendorf
Germany

Prof Tobias Maurer
Prof. Dr. med. Tobias Maurer, FEBU 26.10.1975
Faculty
Martini-Klinik and Department of Urology University of Hamburg-Eppendorf, Germany
Martini-Str. 52 Gebäude Ost 46, 20246 Hamburg, Germany
Phone: +49 (0)40 7410-51300
Email: t.maurer@uke.de
Web: https://www.martini-klinik.de/klinik/team/faculty/prof-maurer
Educational and Professional Experience
Since 2018 – Faculty at the Martini-Klinik Prostate Cancer Center, University of Hamburg-Eppendorf, Hamburg, Germany
2017–2018 – Senior Attending Urologist, Department of Urology, Technical University of Munich (TUM), Klinikum rechts der Isar, Germany
2011–2016 – Attending Urologist, Department of Urology, TUM, Klinikum rechts der Isar
2009–2011 – Urologist, Department of Urology, TUM
1997–2009 – Medical training and residency at the Technical University of Munich
Professional Memberships
European Association of Urology (EAU)
European Society of Urological Imaging (ESUI), Associate Member
German Urology Association (DGU)
Vereinigung Norddeutscher Urologen e.V. (VNU)
Clinical and Scientific Focus
Prostate cancer (imaging, surgery, medical therapy)
PSMA-PET imaging and PSMA-radioguided surgery
Honors and Awards
More than 30 national and international awards and stipends, selected:
2017 – Award for Research and Innovation in Urooncology, German Urological Association (DGU), for PSMA-radioguided surgery
2015 – EAU-AUA Scientific Exchange Programme Stipend (USA)
2011 – Award from the German Society of Immunotherapy (DGFIT)
2000–2002 – Stipend of the German Research Foundation (DFG)
Reviewer Assignments
Reviewer for >40 peer-reviewed journals
Advisory Board, Nature Reviews Urology
Reviewer for grant applications including DFG, NWO, KWF, Wilhelm-Sander-Stiftung, King’s Health Partners R&D Fund, Cancer Research UK
Third-party Funding
Total > €1,000,000, including:
DFG (SFB 824, project B11, co-investigator)
EU FP7 (sub-investigator)
DFG (Graduate College 333 for doctoral thesis)
Clinical Study Experience
Co-Investigator on >30 clinical studies, Principal Investigator on 4, including 3 IITs:
• ProSTone (NCT04271579)
• BioPoP (NCT04324983)
• PräVAC (EUDAMED: CIV-12-07-008204; 2013–2018)
Publication List
285 publications (cumulative IF >1400); h-Index: 62
Selected publications:
• Knipper S et al. Eur Urol. 2022 Jun 16. [PMID: 35718637]
• de Barros HA et al. Eur Urol. 2022 Mar 23. [PMID: 35339318]
• Amiel T et al. J Urol. 2021 Jun. [PMID: 33535796]
• Knipper S et al. Eur Urol. 2020 Dec. [PMID: 33317857]
• Maurer T et al. J Nucl Med. 2020 Jan. [PMID: 31732677]
• Horn T et al. Eur Urol. 2019 Oct. [PMID: 30987843]
• van Leeuwen FWB et al. Nat Rev Urol. 2019 Jan. [PMID: 30644446]
• Maurer T et al. Eur Urol. 2018 Apr. [PMID: 29625755]
• Maurer T et al. J Urol. 2016 May. [PMID: 26682756]
• Maurer T et al. Nat Rev Urol. 2016 Apr. [PMID: 26902337]
Faculty
Martini-Klinik and Department of Urology University of Hamburg-Eppendorf, Germany
Martini-Str. 52 Gebäude Ost 46, 20246 Hamburg, Germany
Phone: +49 (0)40 7410-51300
Email: t.maurer@uke.de
Web: https://www.martini-klinik.de/klinik/team/faculty/prof-maurer
Educational and Professional Experience
Since 2018 – Faculty at the Martini-Klinik Prostate Cancer Center, University of Hamburg-Eppendorf, Hamburg, Germany
2017–2018 – Senior Attending Urologist, Department of Urology, Technical University of Munich (TUM), Klinikum rechts der Isar, Germany
2011–2016 – Attending Urologist, Department of Urology, TUM, Klinikum rechts der Isar
2009–2011 – Urologist, Department of Urology, TUM
1997–2009 – Medical training and residency at the Technical University of Munich
Professional Memberships
European Association of Urology (EAU)
European Society of Urological Imaging (ESUI), Associate Member
German Urology Association (DGU)
Vereinigung Norddeutscher Urologen e.V. (VNU)
Clinical and Scientific Focus
Prostate cancer (imaging, surgery, medical therapy)
PSMA-PET imaging and PSMA-radioguided surgery
Honors and Awards
More than 30 national and international awards and stipends, selected:
2017 – Award for Research and Innovation in Urooncology, German Urological Association (DGU), for PSMA-radioguided surgery
2015 – EAU-AUA Scientific Exchange Programme Stipend (USA)
2011 – Award from the German Society of Immunotherapy (DGFIT)
2000–2002 – Stipend of the German Research Foundation (DFG)
Reviewer Assignments
Reviewer for >40 peer-reviewed journals
Advisory Board, Nature Reviews Urology
Reviewer for grant applications including DFG, NWO, KWF, Wilhelm-Sander-Stiftung, King’s Health Partners R&D Fund, Cancer Research UK
Third-party Funding
Total > €1,000,000, including:
DFG (SFB 824, project B11, co-investigator)
EU FP7 (sub-investigator)
DFG (Graduate College 333 for doctoral thesis)
Clinical Study Experience
Co-Investigator on >30 clinical studies, Principal Investigator on 4, including 3 IITs:
• ProSTone (NCT04271579)
• BioPoP (NCT04324983)
• PräVAC (EUDAMED: CIV-12-07-008204; 2013–2018)
Publication List
285 publications (cumulative IF >1400); h-Index: 62
Selected publications:
• Knipper S et al. Eur Urol. 2022 Jun 16. [PMID: 35718637]
• de Barros HA et al. Eur Urol. 2022 Mar 23. [PMID: 35339318]
• Amiel T et al. J Urol. 2021 Jun. [PMID: 33535796]
• Knipper S et al. Eur Urol. 2020 Dec. [PMID: 33317857]
• Maurer T et al. J Nucl Med. 2020 Jan. [PMID: 31732677]
• Horn T et al. Eur Urol. 2019 Oct. [PMID: 30987843]
• van Leeuwen FWB et al. Nat Rev Urol. 2019 Jan. [PMID: 30644446]
• Maurer T et al. Eur Urol. 2018 Apr. [PMID: 29625755]
• Maurer T et al. J Urol. 2016 May. [PMID: 26682756]
• Maurer T et al. Nat Rev Urol. 2016 Apr. [PMID: 26902337]

A/Prof Alicia Morgans
Dana Farber Cancer Institute
USA

A/Prof Alicia Morgans
Dr. Morgans is an Associate Professor of Medicine at Harvard Medical School, a Genitourinary Medical Oncologist and the Director of the Survivorship Program at Dana-Farber Cancer Institute. As a clinician and investigator, she has expertise in clinical trials and patient-reported outcome measures, as well as incorporating patient preferences and beliefs into clinical decision making. Her research has investigated complications of systemic therapy for prostate cancer survivors, including the study of skeletal, cardiovascular, diabetic, and cognitive complications, and her work has been funded by grants from the Prostate Cancer Foundation , the National Comprehensive Cancer Network, and the Department of Defense. She leads multiple therapeutic and quality of life focused clinical trials for prostate cancer patients, and has participated in the advanced and localized prostate cancer treatment guidelines committees of the American Urologic Association, and the cardio-oncology committee of American Heart Association.
More speakers to be announced
Subscribe for updates
Sign up to the mailing list to be the first to receive conference updates.
Copyright © 2025. ProsTIC 2026 | All Rights Reserved